According to the official report of WuXi PharmaTech, WuXi PharmaTech took the lead in obtaining IPO approval, largely because of its "discount" listing, that is, the scale of raised funds has shrunk dramatically, which does not meet the listing conditions.
Yao Ming Hyde provides integrated, end-to-end new drug research and development and production services for the global biomedical industry.